Cassava Sciences: PTI-125 for Alzheimer's Disease
Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimer’s disease. The new data were presented by the firm’s scientists during a late-breaking oral presentation at the 12thInternational Conference on Clinical Trials on . . .
This content is for paid subscribers.
Impacting News December 30, 2019